CA3062814C - Stable cannabinoid formulations - Google Patents

Stable cannabinoid formulations Download PDF

Info

Publication number
CA3062814C
CA3062814C CA3062814A CA3062814A CA3062814C CA 3062814 C CA3062814 C CA 3062814C CA 3062814 A CA3062814 A CA 3062814A CA 3062814 A CA3062814 A CA 3062814A CA 3062814 C CA3062814 C CA 3062814C
Authority
CA
Canada
Prior art keywords
cannabidiol
formulations
bql
day
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3062814A
Other languages
English (en)
French (fr)
Other versions
CA3062814A1 (en
Inventor
Kiran Kumar Vangara
Huaguang Li
Ningxin YAN
Hung Q. Nguyen
Venkat R. Goskonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Pharmaceuticals Inc
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/499,178 external-priority patent/US20170224634A1/en
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of CA3062814A1 publication Critical patent/CA3062814A1/en
Application granted granted Critical
Publication of CA3062814C publication Critical patent/CA3062814C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3062814A 2017-04-27 2017-09-22 Stable cannabinoid formulations Active CA3062814C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/499,178 US20170224634A1 (en) 2014-05-29 2017-04-27 Stable cannabinoid formulations
US15/499,178 2017-04-27
PCT/US2017/052897 WO2018200024A1 (en) 2017-04-27 2017-09-22 Stable cannabinoid formulations

Publications (2)

Publication Number Publication Date
CA3062814A1 CA3062814A1 (en) 2018-11-01
CA3062814C true CA3062814C (en) 2023-11-14

Family

ID=63920361

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3062814A Active CA3062814C (en) 2017-04-27 2017-09-22 Stable cannabinoid formulations

Country Status (4)

Country Link
EP (2) EP4516355A3 (enExample)
JP (5) JP2020517727A (enExample)
CA (1) CA3062814C (enExample)
WO (1) WO2018200024A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP4516355A3 (en) * 2017-04-27 2025-05-28 Fresh Cut Development, LLC Stable cannabinoid formulations
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
MX2021006912A (es) 2018-12-11 2021-08-24 Disruption Labs Inc Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas.
GB2584140A (en) * 2019-05-23 2020-11-25 Gw Res Ltd Use of cannabidiol in the treatment of epileptic spasms
MX2022002548A (es) * 2019-09-09 2022-03-22 Cardiol Therapeutics Inc Composiciones medicinales estables de cannabidiol.
CA3157812C (en) * 2019-10-25 2024-10-22 Cardiol Therapeutics Inc. CANNABIDIOL COMPOSITIONS INTENDED FOR USE IN THE TREATMENT OF HEART CONDITIONS
GB2588461A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of absence epilepsy
WO2022064204A1 (en) * 2020-09-24 2022-03-31 Nicoventures Trading Limited Formulation
AU2021348345B2 (en) * 2020-09-24 2024-07-25 Nicoventures Trading Limited Packaged formulation
WO2023286047A1 (en) * 2021-07-13 2023-01-19 Epm (Ip), Inc. Cannabidiolic acid esters for treating prader-willi syndrome
US20250025482A1 (en) * 2021-07-28 2025-01-23 GW Research Limited Use of cannabidiol in the treatment of epilepsy
EP4601629A1 (en) * 2022-10-12 2025-08-20 Leiutis Pharmaceuticals LLP Novel liquid oral formulations of cannabidiol
CN115887426A (zh) * 2022-11-18 2023-04-04 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备核辐射损伤后骨髓恢复药物中的应用
CN116444351A (zh) * 2022-11-18 2023-07-18 中国人民解放军军事科学院军事医学研究院 一种核辐射损伤中对小肠有保护作用的天然小分子化合物
CN116172988A (zh) * 2022-11-18 2023-05-30 中国人民解放军军事科学院军事医学研究院 大麻二酚用于制备急性放射病的药物的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514060A (pt) * 2004-08-03 2008-05-27 Orexigen Therapeutics Inc combinação de bupropion e um segundo composto para acarretar a perda de peso
CA2630241A1 (en) * 2005-11-23 2007-05-31 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
WO2011150338A1 (en) * 2010-05-27 2011-12-01 Zafgen Corporation Methods of treating obesity
AU2015266897B2 (en) * 2014-05-29 2020-07-30 Fresh Cut Development, Llc Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US20160367496A1 (en) * 2014-05-29 2016-12-22 Insys Development Company, Inc. Stable cannabinoid formulations
US20160271252A1 (en) * 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations
EP4516355A3 (en) * 2017-04-27 2025-05-28 Fresh Cut Development, LLC Stable cannabinoid formulations

Also Published As

Publication number Publication date
EP3615079B1 (en) 2025-02-12
JP2025118787A (ja) 2025-08-13
EP3615079C0 (en) 2025-02-12
CA3062814A1 (en) 2018-11-01
JP2024161363A (ja) 2024-11-19
EP4516355A3 (en) 2025-05-28
EP3615079A4 (en) 2020-09-23
JP2025118786A (ja) 2025-08-13
WO2018200024A1 (en) 2018-11-01
EP3615079A1 (en) 2020-03-04
EP4516355A2 (en) 2025-03-05
JP2022130390A (ja) 2022-09-06
JP2020517727A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
AU2022201441B2 (en) Stable cannabinoid formulations
CA3062814C (en) Stable cannabinoid formulations
US20250017875A1 (en) Stable cannabinoid formulations
US20220054450A1 (en) Stable cannabinoid formulations
US20160271252A1 (en) Stable cannabinoid formulations
US20170224634A1 (en) Stable cannabinoid formulations
US20220125932A1 (en) Stable cannabinoid formulations
US11331279B2 (en) Stable cannabinoid formulations
CA3025702C (en) Stable cannabinoid formulations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101

EEER Examination request

Effective date: 20211101